Baxdrostat

Last updated

Baxdrostat
Baxdrostat.svg
Clinical data
ATC code
  • None
Identifiers
  • N-[(8R)-4-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C22H25N3O2
Molar mass 363.461 g·mol−1
3D model (JSmol)
  • CCC(=O)N[C@@H]1CCCC2=C1C=NC=C2C3=CC4=C(C=C3)N(C(=O)CC4)C
  • InChI=InChI=1S/C22H25N3O2/c1-3-21(26)24-19-6-4-5-16-17(12-23-13-18(16)19)14-7-9-20-15(11-14)8-10-22(27)25(20)2/h7,9,11-13,19H,3-6,8,10H2,1-2H3,(H,24,26)/t19-/m1/s1
  • Key:VDEUDSRUMNAXJG-LJQANCHMSA-N

Baxdrostat is an investigational drug that is being evaluated for the treatment of hypertension. [1] It is an aldosterone synthase inhibitor. [2] [3]

Contents

Mechanism of action

Aldosterone dysregulation contributes significantly to the pathogenesis of resistant hypertension. [4] While conventional drugs act by blocking the mineralocorticoid receptor, baxdrostat, an aldosterone synthase inhibitor, targets the aldosterone synthesis directly. [2]

Clinical trials

BrigHTN

In adults with treatment-resistant hypertension, treatment with baxdrostat at doses of 1 mg or 2 mg daily produced significantly greater reductions in systolic blood pressure over 12 weeks compared to placebo. [5]

BaxHTN

BaxHTN is a phase 3 trial. [6] It found that adding once-daily baxdrostat to standard antihypertensive therapy led to significantly greater reductions in seated systolic blood pressure at 12 weeks compared with placebo, in adults with uncontrolled or resistant hypertension. [7] [6]

References

  1. ↑ "Baxdrostat - CinCor Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. 1 2 Dogra S, Shah S, Gitzel L, Pusukur B, Sood A, Vyas AV, et al. (November 2023). "Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension". Current Problems in Cardiology. 48 (11) 101918. doi:10.1016/j.cpcardiol.2023.101918. PMID   37399857. S2CID   259320969.
  3. ↑ Awosika A, Cho Y, Bose U, Omole AE, Adabanya U (October 2023). "Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension". Expert Opinion on Investigational Drugs. 32 (11): 985–995. doi:10.1080/13543784.2023.2276755. PMID   37883217. S2CID   264517675.
  4. ↑ Acelajado MC, Calhoun DA (January 2011). "Aldosteronism and resistant hypertension". International Journal of Hypertension. 2011 837817. doi: 10.4061/2011/837817 . PMC   3034938 . PMID   21331160.
  5. ↑ Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. (February 2023). "Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension". The New England Journal of Medicine. 388 (5): 395–405. doi:10.1056/NEJMoa2213169. PMID   36342143.
  6. 1 2 Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ES, et al. (October 2025). "Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension". The New England Journal of Medicine. 393 (14): 1363–1374. doi:10.1056/NEJMoa2507109. PMC   7618089 . PMID   40888730.
  7. ↑ "Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial". www.astrazeneca.com (in Azerbaijani). 30 August 2025. Retrieved 4 November 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.